Alpha-GPC

Alpha-GPC has real acute benefits for power output and age-related cognitive decline, but chronic high-dose use is difficult to justify after the 2021 stroke signal. A 10-year cohort of 12 million South Korean adults (Lee et al., PMID 34817582) found users had 46% higher stroke risk via TMAO, with a clear dose-response relationship. The performance and cognitive data are solid, 600mg pre-exercise increases power output, and 1,200mg daily improved cognition and reversed temporal lobe atrophy in mild-to-moderate Alzheimer's. Anyone with cardiovascular risk factors should skip it; everyone else should cycle rather than take it daily indefinitely.

For athletic performance, research shows that 600mg taken 60-90 minutes before exercise increases power output compared to placebo. Bellar et al. (2015, n=48) found a statistically significant 98.8 Newton increase in isometric mid-thigh pull peak force after 6 days at 600mg. Ziegenfuss et al. (2008) found a 14% improvement in peak bench press power and a 44-fold GH surge vs 2.6-fold placebo. A separate study (Perez-Pinero et al., PMC5629791) found 250mg improved maximum velocity and mechanical power during countermovement jump more than 500mg, caffeine 200mg, or placebo - suggesting a non-linear dose-response where over-saturation may be counterproductive. The performance research is promising but still moderate in size.

For cognitive enhancement in healthy adults, the evidence has strengthened recently. Marcus et al. 2024 (n=20, DB crossover) showed both 630mg and 315mg improved executive function (Stroop performance) vs placebo. Tamura et al. 2021 found 400mg increased self-reported motivation without altering mood. This healthy-adult nootropic signal emerged primarily from 2020-2024 research.

For cognitive decline in elderly populations, the evidence is the strongest. A large multicenter trial found that 1,200mg/day over 180 days produced significant cognitive improvements in patients with mild to moderate Alzheimer's dementia. A subsequent structural MRI trial found that 1,200mg/day for 36 months combined with donepezil 10mg reversed atrophy in the temporal lobe, hippocampus, and amygdala - donepezil monotherapy showed no structural improvement. A 2025 meta-analysis (Sagaro et al., PMID: 41426989) found Alpha-GPC significantly outperformed citicoline on overall clinical status (SCAG WMD: -3.92), though both compounds performed equally on direct memory recall.

The most significant safety concern: a 10-year longitudinal cohort study (Lee et al. 2021, n=12 million, South Korea NHIS database) found that Alpha-GPC users had a 46% higher risk of stroke compared to non-users (adjusted HR 1.46, 95% CI 1.43-1.48). This elevated risk applied to both ischemic stroke (aHR 1.36) and hemorrhagic stroke (aHR 1.36), with a dose-response relationship - higher cumulative intake correlated with higher risk. The mechanism is TMAO: gut bacteria possessing the cutC gene metabolize choline into trimethylamine (TMA), which the liver enzyme FMO3 oxidizes to TMAO - a compound that activates inflammatory cascades, accelerates atherosclerosis, and promotes platelet hyperreactivity. After propensity score matching, the stroke risk remained at aHR 1.43, and persisted even after excluding events in the first 4 years (eliminating reverse causality). Preclinical data in ApoE-/- mice confirms Alpha-GPC feeding shifts the gut microbiome toward TMA-producing taxa and accelerates atherosclerotic lesion progression. This is observational data from a prescription-use population, not a randomized trial, and the users were older adults with existing health conditions. But the size, consistency, and mechanistic plausibility of the signal warrants serious caution for chronic high-dose use.